Search

Displaying results 9991 - 10000 of 10000 in total
  1. Drug

    Nevanimibe

    go.drugbank.com/drugs/DB16254
    Investigational

    Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).

  2. Drug

    RH-1

    go.drugbank.com/drugs/DB04090
    Investigational

    RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.

  3. Drug

    Misonidazole

    go.drugbank.com/drugs/DB11716
    Investigational

    Misonidazole is under investigation in clinical trial NCT00038038 (Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole).

  4. Drug

    Funapide

    go.drugbank.com/drugs/DB11769
    Investigational

    Funapide has been used in trials studying the treatment of Pharmacokinetics, Postherpetic Neuralgia, and Osteoarthritis of the Knee.

  5. Drug

    Delanzomib

    go.drugbank.com/drugs/DB11956
    Investigational

    Delanzomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.

  6. Drug

    Omarigliptin

    go.drugbank.com/drugs/DB11992
    Investigational

    Omarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.

  7. Drug

    Recoflavone

    go.drugbank.com/drugs/DB12058
    Investigational

    Recoflavone has been used in trials studying the treatment of Acute Gastritis, Dry Eye Syndrome, and Chronic Gastritis.

  8. Drug

    Nagrestipen

    go.drugbank.com/drugs/DB12075
    Investigational

    Nagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.

  9. Drug

    Enobosarm

    go.drugbank.com/drugs/DB12078
    Investigational

    Enobosarm has been used in trials studying the treatment of Stress Urinary Incontinence and Triple Negative Breast Cancer.

  10. Drug

    Selicrelumab

    go.drugbank.com/drugs/DB14958
    Investigational

    Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).